Advertisement

Availability of Alpha-Emitting Radioisotopes by Reactor and Accelerator Production and via Decay of Naturally Occurring Parents

  • F. F. (Russ) Knapp
  • Ashutosh Dash
Chapter

Abstract

Because of the high LET, interest in the use of alpha-emitting radioisotopes for targeted therapy has rapidly increased over the last decade. A variety of candidates are available from decay of naturally occurring species such as 229Th and also via both accelerator and reactor production routes (Chaps. 5 and 6). The chemistry required for separation and purification of these actinide species is complex and requires multi-step sequential procedures. Therapeutic applications of alpha-emitting radioisotopes primary focus on oncology and include tumor therapy and palliation of skeletal metastases. The radiopharmaceuticals which have been prepared with alpha emitters and the highlights of preclinical studies and status of clinical applications are discussed in subsequent chapters. This chapter is focused on the production and process chemistry required to provide these alpha emitters for subsequent radiolabeling and biological evaluation.

Keywords

Alpha Emitter Titanium Phosphate Chlorinate Cobalt Dicarbollide Daughter Radionuclide High Flux Isotope Reactor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Atcher RW, Firedman AM, Hines J. Isotopic generator for bismuth-212 and lead-212 from radium, US Patent 4,663,129, May 5, 1987.Google Scholar
  2. Atcher RW, Friedman AM, Hines JJ. An improved generator for the production of 212Pb and 212Bi from 224Ra. Int J Radiat Appl Instrum A. 1988;39:283–6.CrossRefGoogle Scholar
  3. Boll RA, Mirzadeh S, Kennel SJ. Optimization of radiolabeling of immunoproteins with 225Bi. Radiochimica Acta. 1997,79:145–9.Google Scholar
  4. Davis IA, Glowienka KA, Boll RA, Deal KA, Brechbiel MW, Stabin M, Bochsler PN, Mirzadeh S, Kennel SJ. Comparison of 225actinium chelates: tissue distribution and radiotoxicity. Nucl Med Biol. 1999;26(5):581–9.PubMedCrossRefGoogle Scholar
  5. Deal KA, Davis IA, Mirzadeh S, et al. Improved in vivo stability of actinium-225 macrocyclic complexes. J Med Chem. 1999;42(15):2988–92.PubMedCrossRefGoogle Scholar
  6. Durbin PW, Asling CW, Jeung N, et al. The metabolism and toxicity of radium-223 in rats. Berkeley: University of California Radiation Laboratory; 1958.CrossRefGoogle Scholar
  7. Firestone RB, Eksrom LP. Radioactive elements, version 2.1. LBNL, USA. http://ie.lbl.gov/toi/index.asp; 2004.
  8. Geerlings MW, Kaspersen FM, Apostolidis C, et al. The feasibility of  225Ac as a source of alpha-particles in radioimmunotherapy. Nucl Med Commun. 1993;14:121–5.Google Scholar
  9. Guseva LI. A tandem generator system for production of 223Ra and 211Pb/211Bi in DTPA solutions suitable for potential application in radiotherapy. J Radioanalyt Nucl Chem. 2009;281:577–83.CrossRefGoogle Scholar
  10. Harrison GE, Carr TE, Sutton A, et al. Plasma concentration and excretion of calcium-47, strontium-85, barium-133 and radium-223 following successive intravenous doses to a healthy man. Nature. 1966;209:526–7.PubMedCrossRefGoogle Scholar
  11. Henriksen G, Schoultz BW, Michaelsen TE, et al. Sterically stabilized liposomes as a carrier for alpha-emitting radium and actinium radionuclides. Nucl Med Biol. 2004;31:441–9.PubMedCrossRefGoogle Scholar
  12. Howell RW, Goddu SM, Narra VR, et al. Radiotoxicity of gadolinium-148 and radium-223 in mouse testes: relative biological effectiveness of alpha-particle emitters in vivo. Radiat Res. 1997;147:342–8.PubMedPubMedCentralCrossRefGoogle Scholar
  13. Kennel SJ, Mirzadeh S. Vascular targeted radioimmunotherapy with 213Bi–an alpha-particle emitter. Nucl Med Biol. 1998;25(3):241–6.PubMedCrossRefGoogle Scholar
  14. McDevitt MR, Sgouros G, Finn DR, et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med. 1998;25(9):1341–51.PubMedCrossRefGoogle Scholar
  15. McDevitt MR, Ma D, Lai LT, et al. Tumor therapy with targeted atomic nanogenerators. Science. 2001;294(5546):1537–40.PubMedCrossRefGoogle Scholar
  16. McLaughlin MF, Woodward J, Boll RA, et al. Gold coated lanthanide phosphate nanoparticles for targeted alpha therapy. PLoS One. 2013;8(1):e54531.PubMedPubMedCentralCrossRefGoogle Scholar
  17. Melville G, Liu SF, Allen BJ. A theoretical model for the production of Ac-225 for cancer therapy by photon induced transmutation of Ra-226. J Appl Radiat Isot. 2006;64(9):979–88.CrossRefGoogle Scholar
  18. Mirzadeh S, Garland MA. US Patent 7,852,975 B2, issued Dec. 14, 2010. Production of thorium-229 using helium nuclei.Google Scholar
  19. Morgenstern A, Apostolidis C, Bruchertseifer F, et al. Cross-section of the reaction 232Th(p,3n)230Pa for production of 230U for targeted alpha therapy. Appl Radiat Isot. 2008a;66(10):1275–80.Google Scholar
  20. Morgernstern A, Lebeda O, Strusa J, et al. Production of 230U/226Th for targeted alpha therapy via proton irradiation of 231Pa. Anal Chem. 2008b;80(22):8763–70.Google Scholar
  21. Schwartz J, Jaggi JS, O’Donoghue JA, et al. Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody. Phys Med Biol. 2011;56(3):721–33.PubMedPubMedCentralCrossRefGoogle Scholar
  22. Shishkin DN, Krupitskii SV, Kuznetsov SA. Extraction generator of 223Ra for nuclear medicine. Radiokhimiya. 2011;53(4):343–5.Google Scholar
  23. Soderquist CZ, McNamara BK, Fisher DR. Production of high-purity radium-223 from legacy actinium-beryllium neutron sources. Curr Radiopharm. 2012;5(3):244–52.PubMedCrossRefGoogle Scholar
  24. Van Geel JNC, Fuger JJ, Koch L. Method for producing actinium-225 and bismuth-213. United States Patent 5355394; 1994.Google Scholar
  25. Weidner JW, Mashnik SG, John KD. 225Ac and 223Ra Production via 800 MeV proton irradiation of natural thorium targets. Appl Radiat Isot. 2012;70:2590–5.PubMedCrossRefGoogle Scholar
  26. Zhuikov BL, Kalmykov SN, Ermolaev SV, et al. Production of 225Ac and 223Ra by irradiation of Th with accelerated protons. Radiochemistry. 2012;53(1):73–80.CrossRefGoogle Scholar

Copyright information

© Springer India 2016

Authors and Affiliations

  • F. F. (Russ) Knapp
    • 1
  • Ashutosh Dash
    • 2
  1. 1.Nuclear Security and Isotope DivisionOak Ridge National LaboratoryOAK RIDGEUSA
  2. 2.Isotope Production and Applications DivisionBhabha Atomic Research CentreMumbaiIndia

Personalised recommendations